Brutalist Biotech

• Ronovo Surgical raises $67M for modular laparoscopic robot with J&J backing (9h)
• OraSure comes under investor pressure, with potential proxy fight: report (10h)
• FDA misinterpreted efficacy data that prompted DMD rejection, Capricor claims (11h)
• Pfizer vet takes CEO post at new, phase 3-ready regenerative medicine biotech (12h)
• Eli Lilly invites biotechs to use its new AI platform to help develop their own drugs (15h)

• Lilly to give biotech startups access to AI tools (5h)
• Novartis to gain heart drug in $1.4B deal for Tourmaline Bio (10h)
• BioNTech says dual-acting lung cancer drug helped shrink tumors (1d)
• A new class of sleep drugs draws Wall Street’s attention (1d)
• Pfizer, BioNTech showcase new data supporting COVID booster (1d)

• Trump directs more FDA enforcement of pharma ads (3h)
• Endpoints livestream: Will the XBI ever go up again? (8h)
• Lundbeck to transfer commercial drugs to three partners in 27 markets (8h)
• HHS outlines vaccine, drug strategy in new MAHA report (8h)
• Eric Green, who the Trump administration ousted from NIH, urges optimism (9h)

• Second MAHA Report Emphasizes Chronic Disease, Tilts at Vaccine Reform (5h)
• Novartis’ Busy BD Team Keeps 2025 Bolt-On Deal Promises (11h)
• FDA Turns Away Ultra-Rare Disease Therapy (13h)
• BMS, BioNTech Post Geographically Consistent Mid-Stage PD-L1/VEGF Data in SCLC (13h)
• Neuroscience Biotech LB Files for $228M IPO to Support Phase III Plans (13h)

• Monarez to testify in Senate hearing next week (34m)
• FDA pledges to crack down on DTC pharma ads (2h)
• RFK Jr. ally’s ‘smoking gun’ study on vaccines and chronic illness is fundamentally flawed (5h)
• Dozens of lawmakers urge HHS to abandon a pilot initiative for the controversial 340B program (5h)
• An API supplier in India wants you to know its metal detector is working just fine (6h)

• Integra Therapeutics Raises €10.7 Million to Advance Gene Writing Platform and CAR-T Validation (10h)
• CHARM Therapeutics Raises $80 Million to Advance Next-Generation Menin Inhibitors for AML (10h)
• Ketryx Gets $39 Million to Expand AI Compliance Infrastructure for Life Sciences (11h)
• Enveda Secures $150M Series D, Advances Lead Program & Adds Ex-Pfizer R&D Chief to Board (13h)
• Lilly Offers Biotechs Access to AI Models Trained on $1B in Proprietary Drug Discovery Data (13h)

Drug Channels

• Drug Channels Leadership Forum 2026: Full Agenda Now Available (Spoiler: Even more awesome than 2025!) (22h)
• If Banks Sync Data in Real Time, Why Can't Patient Services? (5d)
• Hubs: The Bridge Between Patients and Providers (2w)
• Why the Pharmacy Supply Chain Is Broken and How SmithRx Is Fixing It (3w)
• Drug Channels News Roundup, August 2025: White Bagging Battles, Private Label Price Hypocrisy, 340B Patient Problems, and UnitedHealth Group’s Woes (3w)

• Servier acquires Kaerus Bioscience’s FXS candidate for US$450m (21h)
• NRG Therapeutics Ltd bags £50m in Series B financing (1d)
• BioFlo® 120 – Performance Meets Value (2d)
• BioNTech‘s breast cancer ADC outperforms Roche’s Kadcyla (2d)
• Alt protein: EASAC sees immediate need for action (2d)

Drug Hunter

• PF-07293893 (5h)
• Lessons in LAI: Discovery of a Long-Acting Injectable TAK1 Inhibitor (1d)
• Glossary: AI for Drug Discovery (1d)
• Cracking the Entry Code: CD36 as a Key Receptor for Heterobifunctional Degrader Cellular Uptake (4d)
• PF-07853578 (5d)

• Top biotech deals in August 2025 (13h)
• Advanced expression vector design to overcome challenges in developing multichain biotherapeutics (18h)
• With Lykos CRL now public, FDA opens new era of accountability (1d)
• Closing treatment gaps in yellow fever: are germ-free egg-based vaccines the answer? (4d)
• Navigating the biotech development journey from first steps to global scale with Lonza (4d)

Bio IT World

• First-in-Class Dietary Supplement a Potentially Big Win for Babies (11h)
• Microbiome-Based Therapies Hold Promise for Chronic Diseases (5d)
• Psilocybin Being Investigated as an Anti-Aging Agent (6d)
• Machine Learning Penetrance Score Predicts Genetic Variant Impacts (1w)
• Ultima’s ppmSeq Pushes Sequencing to New Levels of Accuracy (2w)

• MRI Technique Detects Brain Iron, Indicates Risk of Cognitive Decline (4h)
• Alzheimer’s Vaccine Candidate ALZ-101 Begins Phase II Clinical Study (14h)
• Servier Buys Fragile X Syndrome Candidate for up to $450M (1d)
• Prior Dengue Infection Rewires Immunity, Boosts Vaccine Response (1d)
• Flu Severity in Older Adults Mediated by ApoD Regulation of Innate Antiviral Immunity (1d)

• FDA Approves Inlexzo for Some With Non–Muscle Invasive Bladder Cancer (5h)
• Change of Season Musings As A Breast Cancer Survivor (6h)
• Lunsumio plus Polivy Associated With Responses in MCL (7h)
• Standing Up to Cancer with Lynch Syndrome (9h)
• Zidesamtinib Elicits Responses in ROS1-Positive NSCLC (10h)

Contract Pharma*

• Packaging Innovation with Purpose (7h)
• Medable Launches Agent Studio (8h)
• Abselion Launches AAVX and AAV9 Quantification Kits (8h)
• Parexel Establishes New Global HQ in Raleigh, NC (9h)
• Circle Pharma Partners with Eli Lilly to Boost AI-Driven Drug Discovery (12h)

• Quotient Sciences and CPI launch RNA drug development venture (17h)
• Bluejay begins phase 3 trial of brelovitug for hepatitis D (17h)
• Eisai unveils promising phase 1b data for narcolepsy drug E2086 (1d)
• AlzeCure presents phase 2 data on ACD440 at NeuPSIG 2025 (5d)
• Resolution Therapeutics doses first patient in EMERALD study of RTX001 (6d)

• Strive Health Secures $550M to Advance Value-Based Kidney Care Model (4h)
• Corewell Health Touts Success of Virtual Lifestyle Medicine Program with Nudj Health (5h)
• Novartis’s $1.4B Tourmaline Acquisition Brings Heart Drug That Could Rival Novo Nordisk, CSL Meds (6h)
• The Most Powerful Tool in Healthcare Marketing: A Patient’s Voice (12h)
• From Hospital to Home Without the Headaches: How Technology Can Smooth the Transition (13h)

• Nobel laureate David Baltimore dies at 87 (7h)
• Opinion: Exploitation persists in academic science—here’s what we can do (7h)
• Business briefing for September 9 (9h)
• Greening Chemistry: Don’t let resistance to change stop students from changing the world (9h)
• Manganese edges into the realm of noble-metal photochemistry (10h)

The Pharma Letter*

• Scenic Biotech names Roland Bürli as CSO (11h)
• Patients the ‘North Star’ for Sionna-bound Caroline Stark Beer (11h)
• Brinsupri massively overpriced at current rates, claims ICER (11h)
• Novartis to acquire Tourmaline Bio (12h)
• FDA rejection leaves Saol searching for a path forward in rare pediatric disease (13h)

• FDA Approves Intravesical Gemcitabine Delivery for Bladder Cancer (6h)
• Talquetamab Dose Modification Maintains Efficacy in Multiple Myeloma (7h)
• FDA Grants Breakthrough Therapy Designation to Olomorasib is KRAS G12C NSCLC (9h)
• I-DXd Shows Promise in Treating Extensive-Stage SCLC (11h)
• FDA Grants Orphan Drug Designation to Novel Glioblastoma Therapy (12h)

• Degunkification (5h)
• Silent RNA (1d)
• An Underappreciated Fate of Drugs in Vivo (4d)
• Stirring Bars are Superstition? (5d)
• Nuclear Fusion in Palladium Metal. No, Really. (6d)

• HHS, FDA drop major DTC advertising policy changes (52m)
• Lilly lines up Julianne Moore to front brain health campaign (8h)
• Lundbeck retreats from dozens of markets, slashing staff (9h)
• Lilly offers AI discovery models to biotech partners (10h)
• ICER says GLP-1s 'still have serious affordability issues' (11h)

• New NICE thresholds is good news for ultra-rare disease drugs, says biotech (10h)
• Registration open for DDW Symposium in London (13h)
• Transforming drug discovery with AI and digital labs: Last chance to register (18h)
• Treatment for post-natal depression authorised in UK (1d)
• From knowledge to creation: keeping up with AI (1d)